pexidartinib

Plexxikon MOA pexidartinib

Targeted Indication Status Sites link to clinicaltrials.gov

TGCT
PVNS
GCT-TS

Phase 3

40+ sites worldwide

NCT02371369

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

West RB et al. PNAS. 2006; 103(3); 690-5. Quail DF, Joyce JA. Nat Med. 2013; 19(11); 1423-37.
Tap WD et al. NEJM. 2015; 373(5); 428-37.